Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 18, 2013, Pages 7434-7439

  Laurin, Mélanie ^a,b   Huber, Jennifer ^a   Pelletier, Ariane ^a   Houalla, Tarek ^a   Park, Morag ^c   Fukui, Yoshinori ^d   Haibe Kains, Benjamin ^a,b   Muller, William J ^c   Côté, Jean François ^a,b,e  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d KYUSHU UNIVERSITY   (Japan)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

DOCK180; ErbB2; RhoGEF; Tumorigenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INTERFERON; PROTEIN; PROTEIN C JUN; PROTEIN DOCK1; RECEPTOR TRANSPORTER PROTEIN 4; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER METASTASIS; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CYTOKINESIS; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; LUNG NEOPLASMS; MICE; NEUREGULIN-1; PROGNOSIS; RAC GTP-BINDING PROTEINS; RECEPTOR, ERBB-2; RHO GTP-BINDING PROTEINS; TREATMENT OUTCOME;

ANIMALIA;

EID: 84876890072     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1213050110     Document Type: Article

References (30)

1. Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012) Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11(6):479-497.
2. Perou CM, et al. (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752.
3. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2):177-184.
4. Slamon DJ, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182. (Pubitemid 17231334)
5. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7(5):389-397. (Pubitemid 46652484)
6. Steeg PS (2006) Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 12(8):895-904.
7. Sanz-Moreno V, et al. (2008) Rac activation and inactivation control plasticity of tumor cell movement. Cell 135(3):510-523.
8. Sosa MS, et al. (2010) Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 40(6):877-892.
9. Côté JF, Vuori K (2007) GEF what? Dock180 and related proteins help Rac to polarize cells in new ways. Trends Cell Biol 17(8):383-393.
10. Duchek P, Somogyi K, Jékely G, Beccari S, Rørth P (2001) Guidance of cell migration by the Drosophila PDGF/VEGF receptor. Cell 107(1):17-26. (Pubitemid 32972034)
11. Smith HW, Marra P, Marshall CJ (2008) uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J Cell Biol 182(4):777-790.
12. Feng H, et al. (2011) Activation of Rac1 by Src-dependent phosphorylation of Dock180 (Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 121(12):4670-4684.
13. Feng H, et al. (2012) Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci USA 109(8):3018-3023.
14. Haibe-Kains B, et al. (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104(4):311-325.
15. Nishikimi A, et al. (2012) Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2. Chem Biol 19(4):488-497.
16. Ursini-Siegel J, et al. (2008) ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 27(6):910-920. (Pubitemid 351417168)
17. Guo W, et al. (2006) Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126(3):489-502. (Pubitemid 44163602)
18. Kiyokawa E, et al. (1998) Activation of Rac1 by a Crk SH3-binding protein, DOCK180. Genes Dev 12(21):3331-3336. (Pubitemid 28520981)
19. Northey JJ, et al. (2008) Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol 28(10):3162-3176. (Pubitemid 351657082)
20. Khodarev NN, et al. (2004) STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101(6):1714-1719. (Pubitemid 38234220)
21. Bektas N, et al. (2008) The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res 10(4):R58.
22. Tsai YC, et al. (2011) Interferon-β signaling contributes to Ras transformation. PLoS ONE 6(8):e24291.
23. Desai SD, et al. (2012) ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood) 237(1):38-49.
24. Strumane K, Rygiel T, van der Valk M, Collard JG (2009) Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice. J Cancer Res Clin Oncol 135(1):69-80.
25. Sanematsu F, et al. (2010) DOCK180 is a Rac activator that regulates cardiovascular development by acting downstream of CXCR4. Circ Res 107(9):1102-1105.
26. Diaz N, et al. (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12(1):20-28. (Pubitemid 43166171)
27. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ (2009) Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 69(17):6823-6830.
28. Huck L, Pontier SM, Zuo DM, Muller WJ (2010) beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 107(35):15559-15564.
29. Raven JF, et al. (2011) Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 10(5):794-804.
30. Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H (2004) RTP family members induce functional expression of mammalian odorant receptors. Cell 119(5):679-691. (Pubitemid 39535755)